A Study of LY3305677 in Healthy Participants

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

66 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-12-05

Study Completion Date

2017-07-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the safety of LY3305677 and any side effects that might be associated with it.

This study will also look at how much LY3305677 gets into the blood stream, how long it takes the body to remove it.

This study involves a single dose of LY3305677 administered by subcutaneous injection (SC).

Participation in this study is expected to last up to 16 weeks.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of LY3200327 in Healthy Participants

NCT02595736

Healthy

COMPLETED PHASE1

A Study of LY3461767 in Healthy Participants

NCT04352114

Healthy

COMPLETED PHASE1

A First-In-Human Study of LY3985297 in Healthy Participants

NCT06395012

Healthy

COMPLETED PHASE1

A Study of LY3084077 in Healthy Participants

NCT01846702

Healthy Volunteers

COMPLETED PHASE1

A Study of LY3045697 in Healthy Participants

NCT01750853

Healthy Volunteers

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

LY3305677

Single escalating doses of LY3305677 administered subcutaneously (SC)

Group Type EXPERIMENTAL

LY3305677

Intervention Type DRUG

Administered SC

Placebo

Placebo administered SC

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Administered SC

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LY3305677

Administered SC

Intervention Type DRUG

Placebo

Administered SC

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Overtly healthy as determined by medical history and physical examination
* Male participants: will agree to use a reliable method of birth control and will not donate sperm during the study and for at least 3 months following the last dose of the investigational product
* Female participants: women not of child-bearing potential due to surgical sterilization confirmed by medical history or menopause
* First generation Japanese participants or non-Japanese participants
* Have a body weight of more than 50 kilograms (kg)

Exclusion Criteria

* Have participated within the last 3 months in a clinical trial involving an investigational product
* Have known allergies to glucagon-like peptide-1 (GLP-1) analogs, or any components of the formulation, or history of significant atopy
* Have an abnormality in the 12-lead electrocardiogram (ECG) at screening and/or Day -1
* Have undergone any form of bariatric surgery
* Have obvious clinical signs or symptoms of liver disease, acute or chronic hepatitis
* Have a history of acute or chronic pancreatitis or elevation in serum lipase and/or amylase
* Show evidence of human immunodeficiency virus (HIV) or Hepatitis B or C
* Have used or intend to use medications that promote weight loss
* Have donated blood of more than 500 milliliter (mL) within the last month
* Currently smoke more than 10 cigarettes per day

Minimum Eligible Age

20 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes